(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). Its investigational medicinal products comprise R-107, R-131 and R-147. Douglas collaborates with scientific researchers and external medical experts to advance clinical research.
Let's personalize your content